Reuters logo
BRIEF-Amicus Therapeutics says U.S. FDA granted orphan drug designation to ATB200/AT2221 for Pompe disease
September 21, 2017 / 11:44 AM / in 3 months

BRIEF-Amicus Therapeutics says U.S. FDA granted orphan drug designation to ATB200/AT2221 for Pompe disease

Sept 21 (Reuters) - Amicus Therapeutics Inc

* Says ‍U.S. FDA has granted orphan drug designation to ATB200/AT2221​ for Pompe disease​

* Amicus Therapeutics - ‍look forward to announcing new clinical data in all patients from ATB200/AT2221​ study at World Muscle Society in early Oct Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below